A reversible posterior leukoencephalopathy syndrome;Síndrome de leucoencefalopatía posterior reversible

Revista de Neurologia

Volumn 38, Issue 3, 2004, Pages 261-266

  López García, Francisco ^a,b   Amoros Martinez F ^a   Sempere, A P ^a  

^a HOSPITAL VEGA BAJA   (Spain)

^b NONE   (Spain)

Author keywords

Cerebral edema; Hypertensive encephalopathy; Immunosuppressive agents; Leukoencephalopathy; Magnetic resonance; Syndrome

Indexed keywords

ANTIHYPERTENSIVE AGENT; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; TACROLIMUS;

ADULT; AUTOREGULATION; BLOOD PRESSURE; BRAIN EDEMA; CLINICAL ARTICLE; CONTROLLED STUDY; CONVALESCENCE; ECLAMPSIA; ENDOTHELIUM; FEMALE; GRAFT REJECTION; HEMISPHERE; HOSPITALIZATION; HUMAN; HYPERTENSION; HYPERTENSION ENCEPHALOPATHY; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DISEASE; KIDNEY TRANSPLANTATION; LEUKOENCEPHALOPATHY; MALE; NEUROIMAGING; NEUROLOGIC DISEASE; REVIEW; TREATMENT OUTCOME; VASCULAR DISEASE; WHITE MATTER;

EID: 17444445020     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.3803.2003342     Document Type: Review

References (74)

1. Hinchey J, Chaves C, Appignani B, Breen J, Pao L, Wang A, et al. A reversible posterior leukoencephalopathy syndrome. N Engl J Med 1996; 334: 494-500.
2. López-García F, Espinosa-Garriga G. Síndrome de leucoencefalopatá posterior reversible. Rev Clín Esp 2000; 200: 57-9.
3. Mabie WC. Management of acute severe hypertension and encephalopathy. Clin Obstet Gynecol 1999; 42: 519-31.
4. Koch S, Rabinstein A, Falcone S, Forteza A. Diffusion-weighted imaging shows cytotoxic and vasogenic edema in eclampsia. Am J Neuroradiol 2001; 22: 1068-70.
5. Schwartz RB, Jones KM, Kalina P, Bajakian RL, Mantello MT, Garada B, et al. Hypertensive encephalopathy: findings on CT, MR imaging and SPECT imaging in 14 cases. Am J Roentgenol 1992; 159: 379-83.
6. Sheth RD, Riggs JE, Bodensteiner JB, Gutiérrez AR, Ketonen LM, Ortiz OA. Parietal occipital edema in hypertensive encephalopathy: a pathogenic mechanism. Eur Neurol 1996; 36: 25-8.
7. Grivé E, Rovira-Cañellas A, Acebedo G, Alvarez-Sabín J. Leucoencefalopatía reversible relacionada con el tratamiento con ciclosporina. Rev Neurol 1997; 25: 471-3.
8. Jarosz JM, Howlett DC, Cox TC, Bincham JB. Cyclosporine related reversible posterior leukoencephalopathy: MRI. Neuroradiology 1997; 39: 711-5.
9. Torocsik HV, Curless RG, Post J, Tzakis AG, Pearse L. FK506-induced leukoencephalopathy in children with organ transplants. Neurology 1999; 52: 1497-500.
10. Kemper MJ, Sparta G, Laube GF, Miozzari M, Neuhaus TJ. Neuropsychologic side-effects of tacrolimus in pediatric renal transplantation. Clin Transplant 2003; 17: 130-4.
11. Kamar N, Kany M, Bories P, Ribes D, Izopet J, Durand D, et al. Reversible posterior leukoencephalopathy syndrome in hepatitis virus C positive long-term hemodialysis patients. Am J Kidney Dis 2001; 37: 29.
12. Laguna P, Martín T, Marchena MJ, Moya M. Síndrome de leucoencefalopatía posterior reversible secundario a panarteritis nudosa. Med Clin (Barc) 1997; 109: 397-8.
13. Kawano H, Kimura E, Ishizaki M, Nishida Y, Matsumoto N, Yamashita T, et al. Reversible posterior leukoencephalopathy syndrome in two patients with microscopic polyarteritis nodosa. Rinsho Shinkeigaku 2002; 42: 949-53.
14. Ohbu S, Uekusa T, Watanabe F, Chohnabayashi N. Histologic evidence of reversible posterior leukoencephalopathy. Intern Med 1999; 38: 73.
15. López-García F, Tovar-Beltrán J, Espinosa-Garriga G, Sáez-Castañ J, Ull-Laita M, Enríquez-Ascarza R, et al. Varón de 15 años con enfermedad del tejido conectivo que ingresa por hipertensión arterial y convulsiones. Rev Clín Esp 1999; 199: 683-93.
16. Montaner J, Molina C, Álvarez-Sabin J, Ordi J. Manifestaciones neurológicas en la púrpura de Schönlein-Henoch: ¿vasculitis cerebral o leucoencefalopatá posterior reversible? Med Clin (Barc) 2000; 115: 677.
17. Bakshi R, Shaikh ZA, Bates VE, Kinkel PR. Thrombotic thrombocytopenic purpura: brain CT and MRI findings in 12 patients. Neurology 1999; 52: 1285-8.
18. Bennet B, Booth T, Quan A. Late onset seizures, hemiparesis and blindness in hemolytic uremic syndrome. Clin Nephrol 2003; 59: 196-200.
19. Taylor MB, Jackson A, Weller JM. Dynamic susceptibility contrast enhanced MRI in reversible posterior leukoencephalopathy syndrome associated with haemolytic uremic syndrome. Br J Radiol 2000; 73: 438-42.
20. Kastrup O, Maschke M, Wanke I, Diener HC. Posterior reversible encephalopathy syndrome due to severe hipercalcemia. J Neurol 2002; 249: 1563-6.
21. Kupferschmidt H, Bont A, Schnorf H, Landis T, Walter E, Peter J, et al. Transient cortical blindness and bioccipital brain lesions in two patients with acute intermittent porphyria. Ann Intern Med 1995; 123: 598-600.
22. Utz N, Kinkel B, Hedde JP, Bewermeyer H. MR imaging of acute intermittent porphyria mimicking reversible posterior leukoencephalopathy syndrome. Neuroradiology 2001; 43: 1059-62.
23. Antonini G, Morino S, Fiorelli M, Fazi P, Ceschin V, Petti C. Reversal of encephalopathy during treatment with amphotericin-B. J Neurol Sci 1996; 144: 212-3.
24. Worthley SG, McNeil JD. Leukoencephalopathy in a patient taking low dose oral metotrexate therapy for rheumatoid arthritis. J Rheumatol 1995; 22: 335-7.
25. Cohen RB, Abdallah JM, Gray JR, Foss F. Reversible neurologic toxicity in patients treated with standard-dose fludarabine phosphate for mycosis fungoides and chronic lymphocytic leukemia. Ann Intern Med 1993; 118: 114-6.
26. Vaughn DJ, Jarvik JG, Hackney D, Peter S, Stadtmauer EA. High-dose cytarabine neurotoxicity: MR finding during the acute phase. Am J Neuroradiol 1993; 14: 1014-6.
27. Russell MT, Nassif AS, Cacayorin DE, Awwad E, Perman W, Cunphy F. Gemcitabine-associated posterior reversible encephalopathy syndrome: MR imaging and MR spectroscopy findings. Mag Reson Imaging 2001; 19: 129-32.
28. Ito Y, Arahata Y, Goto Y, Hirayama M, Nagamutsu M, Yasuda T, et al. Cisplatin neurotoxicity presenting as reversible posterior leukoencephalopathy syndrome. Am J Neuroradiol 1998; 19: 415-7.
29. Giménez-Mesa E, Martínez-Salio A, Porta-Etessam J, Berbel-García A, Cedena-Romero T, Salama-Bendoyan P. Leucoencefalopatía posterior reversible en un paciente con linfoma no-Hodgkin tras tratamiento con CHOP. An Med Interna 2001; 18: 591-3.
30. Higman MA, Port JD, Beauchamp NJ, Chen AR. Reversible leukoencephalopathy associated with re-infusion of DMSO preserved stemcells. Bone Marrow Transplant 2000; 26: 797-800.
31. Delanty N, Vaughn C, Frucht S, Stubgern P. Erythropoietin associated hypertensive posterior leukoencephalopathy. Neurology 1997; 59: 686-9.
32. Rodrigo E, Ruiz-San Millán JC, Heras M, Piñera C, Fernández-Fresneda G, Sanz de Castro S, et al. Leucoencefalopatía posterior por encefalopatía hipertensiva inducida por eritropoyetina. Nefrología 1999; 4: 360-4.
33. Mathy I, Gille M, Van Raemdock F, Delbeck J, Depre A. Neurological complications of intravenous immunoglobulin (IVIg) therapy: an illustrative case of acute encephalopathy following IVIg therapy and review of the literature. Acta Neurol Belg 1998; 98: 347-51.
34. Rodríguez-Gómez E, Rodríguez-Gómez FJ, Merino MJ, Robledo A, Domínguez-López JM, Ferná ndez-Girón F, et al. Síndrome de leucoencefalopatía posterior reversible, hipertensión severa y abuso de cocaína. Nefrología 2001; 21: 305-8.
35. Ito Y, Niwa H, Iida T, Nagamutsu M, Yasuda T, Yanagi T, et al. Post-transfusion reversible posterior leukoencephalopathy syndrome with cerebral vasoconstriction. Neurology 1997; 49: 1174-5.
36. Zwicker JC, Sila CA. MRI findings in a case of transient cortical blindness after cardiac catheterization. Catheter Cardiovasc Interv 2002; 57: 47-9.
37. Moriarity JL, Lim M, Storm PB, Beauchamp NJ, Olivi A. Reversible posterior leukoencephalopathy occurring during resection or a posterior fossa tumor: case report and review of literature. Neurosurgery 2001; 49: 1237-9.
38. Vázquez E, Lucaya J, Castellote A, Piqueras J, Sainz P, Olivé T, et al. Neuroimaging in pediatric leukemia and lymphoma: differential diagnosis. Radiographics 2002; 22: 1411-28.
39. Provenzale JM, Graham ML. Reversible leukoencephalopathy associated with Graft-versus-Host disease: MR findings. Am J Neuroradiol 1996; 17: 1290-4.
40. Rathi B, Azad RK, Vasudha N, Hissaria P, Sawlani V, Gupta RK. L-asparaginase induced reversible posterior leukoencephalopathy syndrome in a child with acute lymphoblastic leukemia. Pediatr Neurosurg 2002; 37: 203-5.
41. Kwon S, Koo J, Lee S. Clinical spectrum of reversible posterior leukoencephalopathy syndrome. Pediatr Neurol 2001; 24: 361-4.
42. Suminoe A, Matzusaki A, Kira R, Fukunaga N, Nishio T, Hoshina T, et al. Reversible posterior leukoencephalopathy syndromen in children with cancers. J Pediatric Hematol Oncol 2003; 25: 236-9.
43. Sebire G, Husson B, Lasser C, Tardieu M, Dommergues J, Landrieu P. Encephalopathy induced by arterial hypertension: clinical, radiological and therapeutic aspects. Arch Pediatr 1995; 2: 513-8.
44. Tomita M, Takanashi J, Kobayashi K, Nagasawa K, Kurihara A, Okumura K, et al. Four cases of reversible posterior leukoencephalopathy syndrome. No To Hattatsu 2001; 33: 426-9.
45. Singhi P, Subramanian C, Jain V, Singhi S, Ray M. Reversible brain lesions in childhood hypertension. Acta Paediatr 2002; 91: 1005-7.
46. Arroyo HA, Gañez LA, Fejerman N. Encefalopatía posterior en la infancia. Rev Neurol 2003; 37: 506-10.
47. Soylu A, Kavukcu S, Turkmen M, Akbas Y. Posterior leukoencephalopathy syndrome in poststreptococcal acute glomerulonefritis. Pediatr Nephrol 2001; 16: 601-3.
48. Caramés-Bartolomé E, Rodríguez-Sousa C, Morais-Barbosa C. Leucoencefalopatía posterior reversible secundaria a glomerulonefritis. An Esp Pediatr 2002; 56: 474-5.
49. Ikeda M, Itos S, Hataya H, Honda M, Anbo K. Reversible posterior leukoencephalopathy in a patient with minimal-change nephrotic syndrome. Am J Kidney Dis 2001; 37: 30.
50. Henderson JN, Noetzel MJ, McKinstry RC, White DA, Armstrong M, DeBaun MR. Reversible posterior leukoencephalopathy syndrome and silent cerebral infarcts are associated with severe acute chest syndrome in children with sickle cell disease. Blood 2003; 101: 415-9.
51. Antunes NL, Small TN, George D, Boulad F, Lis E. Posterior leukoencephalopathy syndrome may not be reversible. Pediatr Neurol 1999; 20: 241-3.
52. Kahn JS, Romano S, Andeman WA. A reversible posterior leukoencephalopathy syndrome. N Engl J Med 1996; 334: 1745.
53. Sylvester SL, Díaz LA, Port JD, Sterling TR. Reversible posterior leukoencephalopathy in an HIV-infected patient with thrombotic thrombocytopenic purpura. Scand J Infect Dis 2002; 34: 706-9.
54. Giner V, Fernández C, Esteban MJ, Galindo MJ, Forner MJ, Guix J, et al. Reversible posterior leukoencephalopathy secondary to indinavir induced hypertensive crisis: a case report. Am J Hypertens 2002; 15: 465-7.
55. Bravo-Blanco AM, Zarzalejos-Andes JM, Suárez-Gago M, Melón-Pérez C, Esteban-Morcillo J. Síndrome de leucoencefalopatía posterior reversible en un paciente infectado por VIH. Rey Clín Esp 2003; 203: 265-6.
56. Eaton JM. A reversible posterior leukoencephalopathy syndrome. N Engl J Med 1996; 334: 1744-5.
57. Strandgaard S, Paulson OB. Cerebral autoregulation. Stroke 1984; 15: 413-6.
58. Ay H, Buonanno FS, Schaefer PW, Le DA, Wang B, González RG, et al. Posterior leukoencephalopathy without severe hypertension: utility of diffusion-weighted MRI. Neurology 1998; 51: 1369-76.
59. Tajima Y, Isonishi K, Kashiwaba T, Tashiro K. Two similar cases of encephalopathy, possibly a reversible posterior leukoencephalopathy syndrome: Serial findings of magnetic resonance imaging, SPECT and angiography. Intern Med 1999; 38: 54-8.
60. Schaefer PW, Buonanno FS, González RG, Schwamm LH. Diffusion-weighted imaging discriminates between cytotoxic and vasogenic edema in a patient with eclampsia. Stroke 1997; 28: 1082-5.
61. Tweddle D, Windebank KP, Hewson QC, Yule SM. Cyclosporin neurotoxicity after chemoterapy. Br Med J 1999; 318: 1113.
62. Henderson RD, Rajah T, Nicol AJ, Read SJ. Posterior leukoencephalopathy following intrathecal chemoterapy with MRA-documented vasospasm. Neurology 2003; 60: 326-8.
63. Lin JT, Wang SJ, Fuh JL, Hsiao LT, Lirng JF, Chen PM. Prolonged reversible vasospasm in cyclosporin A-induced encephalopathy. Am J Neuroradiol 2003; 24: 102-4.
64. Covarrubias DJ, Luetmer PH, Campeau NG. Posterior reversible encephalopathy syndrome: prognostic utility of quantitative diffusion-weight MR images. Am J Neuroradiol 2002; 23: 1038-48.
65. Eichler FS, Wang P, Wityk RJ, Beauchamp NJ, Barker PB. Diffuse metabolic abnormalities in reversible posterior leukoencephalopathy syndrome. Am J Neuroradiol 2002; 23: 833-7.
66. Donaldson JO. The brain in the eclampsia. Hypertens Pregnancy 1994; 13: 115.
67. Schwartz RB. A reversible posterior leukoencephalopathy syndrome. N Engl J Med 1996; 334: 1743.
68. Pavlakis SG, Frank Y, Kalina P, Chandra M, Lu D. Occipital-parietal encephalopathy: a new name for an old syndrome. Pediatr Neurol 1997; 16: 145-8.
69. Yamamoto T. Reversible posterior leukoencephalopathy syndrome. Is it reversible and thus benign? Intern Med 1999; 38: 4-5.
70. Domínguez R, Famulari A, Vila J. Leucoencefalopatía: la frontera entre lo reversible y lo persistente. Rev Neurol 1997; 25: 2074.
71. Bakshi R, Bates V, Mechtler L, Kinkel P, Kinkel W. Occipital lobe seizures as the major clinical manifestation of reversible posterior leukoencephalopathy syndrome: magnetic resonance imaging findings. Epilepsia 1998; 39: 295-9.
72. Casey SO, Sampaio RC, Michel E, Truwit CHL. Posterior reversible encephalopathy syndrome: utility of fluid-attenuated inversion recovery MR imaging in the detection of cortical and subcortical lesions. Am J Neuroradiol 2000; 21: 1199-206.
73. Provenzale JM, Petrella JR, Cruz LC, Wong JC, Engelter S, Barboriak DP. Quantitative assessment of diffusion abnormalities in posterior reversible encephalopathy syndrome. Am J Neuroradiol 2001; 22: 1455-61.
74. Mulherjee P, McKinstry RC. Reversible posterior leukoencephalopathy syndrome: evaluation with diffusion-tensor MR imaging. Radiology 2001; 219: 756-65.